Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 765,281,600
  • Shares Outstanding, K 949,316
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • EBIT $ 13,467 M
  • EBITDA $ 14,994 M
  • 60-Month Beta 0.43
  • Price/Sales 22.78
  • Price/Cash Flow 107.38
  • Price/Book 54.29

Options Overview Details

View History
  • Implied Volatility 29.82% ( -0.02%)
  • Historical Volatility 25.94%
  • IV Percentile 54%
  • IV Rank 22.56%
  • IV High 55.08% on 08/05/24
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.64
  • Today's Volume 42,039
  • Volume Avg (30-Day) 46,230
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 304,917
  • Open Int (30-Day) 288,099

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 5.49
  • Number of Estimates 8
  • High Estimate 5.59
  • Low Estimate 5.34
  • Prior Year 2.49
  • Growth Rate Est. (year over year) +120.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
769.00 +4.62%
on 10/30/24
937.00 -14.14%
on 10/14/24
-82.61 (-9.31%)
since 10/04/24
3-Month
763.02 +5.44%
on 08/07/24
972.53 -17.27%
on 08/22/24
+29.29 (+3.78%)
since 08/05/24
52-Week
561.65 +43.25%
on 12/15/23
972.53 -17.27%
on 08/22/24
+236.74 (+41.69%)
since 11/03/23

Most Recent Stories

More News
Is Viking Therepautics a Buy Now?

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

VKTX : 63.72 (+0.92%)
LLY : 804.55 (-0.20%)
Why Viking Therapeutics Stock Plummeted After Soaring Today

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?

VKTX : 63.72 (+0.92%)
LLY : 804.55 (-0.20%)
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on an operational basis, driven by higher sales of key non-COVID products like...

NVO : 108.08 (-1.49%)
LLY : 804.55 (-0.20%)
ABBV : 199.96 (-0.25%)
PFE : 27.77 (+0.04%)
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?

Size means little in light of this company's prospects.

NVO : 108.08 (-1.49%)
LLY : 804.55 (-0.20%)
Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis,...

NVO : 108.08 (-1.49%)
LLY : 804.55 (-0.20%)
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip

The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut.

LLY : 804.55 (-0.20%)
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus

Amgen AMGN reported third-quarter 2024 adjusted earnings of $5.58 per share, which beat the Zacks Consensus Estimate of $5.11. Earnings rose 13% year over year as higher revenues offset the impact of higher...

AZN : 67.37 (-5.68%)
NVO : 108.08 (-1.49%)
LLY : 804.55 (-0.20%)
AMGN : 316.91 (-0.72%)
Company News for Oct 31, 2024

Super Micro Computer, Inc. (SMCI) shares plunged 32.7% after Ernst & Young resigned as auditor.  Shares of Eli Lilly and Company (LLY) fell 6.3% after reporting third-quarter 2024 earnings of $1.18 per...

SMCI : 26.50 (+1.81%)
LLY : 804.55 (-0.20%)
ITW : 263.88 (+0.30%)
CLH : 237.70 (+2.02%)
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering

Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors

VKTX : 63.72 (+0.92%)
NVO : 108.08 (-1.49%)
LLY : 804.55 (-0.20%)
GS : 513.00 (+0.30%)
Stocks Plunge Before the Open as Microsoft and Meta Weigh on Sentiment, U.S. Inflation Data and Earnings in Focus

December S&P 500 E-Mini futures (ESZ24) are down -0.77%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -1.09% this morning as investors digested quarterly earnings reports from Microsoft and...

META : 562.87 (+0.39%)
GOOGL : 169.75 (+0.30%)
AAPL : 221.89 (-0.05%)
MO : 53.76 (-0.22%)
BNP.FP : 62.460 (-0.65%)
SMCI : 26.50 (+1.81%)
MRK : 101.66 (-0.21%)
NQZ24 : 20,139.50 (+0.27%)
GRMN : 200.24 (+1.04%)
GLE.FP : 26.885 (-1.12%)
MSFT : 409.50 (+0.25%)
MA : 505.58 (-0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 832.84
2nd Resistance Point 826.51
1st Resistance Point 816.33
Last Price 804.55
1st Support Level 799.82
2nd Support Level 793.49
3rd Support Level 783.31

See More

52-Week High 972.53
Fibonacci 61.8% 815.57
Last Price 804.55
Fibonacci 50% 767.09
Fibonacci 38.2% 718.61
52-Week Low 561.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar